Cargando…
Review on the Role of Epigenetic Modifications in Doxorubicin-Induced Cardiotoxicity
Use of anthracyclines such as doxorubicin (DOX), for the treatment of cancer, is known to induce cardiotoxicity, begetting numerous evaluations of this adverse effect. This review emphasizes the mechanism of how consideration of DOX-induced cardiotoxicity is important for the development of cardiopr...
Autores principales: | Kumari, Himani, Huang, Wan-Hong, Chan, Michael W. Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221144/ https://www.ncbi.nlm.nih.gov/pubmed/32457918 http://dx.doi.org/10.3389/fcvm.2020.00056 |
Ejemplares similares
-
Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity
por: Chen, De-Shu, et al.
Publicado: (2022) -
Demystifying the Relationship Between Metformin, AMPK, and Doxorubicin Cardiotoxicity
por: Singh, Manrose, et al.
Publicado: (2022) -
Exercise Training Preserves Myocardial Strain and Improves Exercise Tolerance in Doxorubicin-Induced Cardiotoxicity
por: Gomes-Santos, Igor L., et al.
Publicado: (2021) -
Exploring the Mechanism of Danshensu in the Treatment of Doxorubicin-Induced Cardiotoxicity Based on Network Pharmacology and Experimental Evaluation
por: Qi, Jia-ying, et al.
Publicado: (2022) -
Identification of novel biomarkers involved in doxorubicin-induced acute and chronic cardiotoxicity, respectively, by integrated bioinformatics
por: Qian, Hongyan, et al.
Publicado: (2023)